- |||||||||| Retrospective data, Review, Journal: Maximizing response to first-line antipsychotics in schizophrenia: a review focused on finding from meta-analysis. (Pubmed Central) - May 8, 2019
Our review of recent studies using meta-analytic techniques has provided evidence that all antipsychotics are not equal in the severity of different side effects and in some measures of clinical efficacy. Comparative analysis and rankings from network meta-analyses can provide guidance to clinicians in choosing the most appropriate antipsychotic for first-line treatment, if used in conjunction with available information of the patient's history of previous clinical response or higher risks for specific side effects.
- |||||||||| Geodon (ziprasidone) / RaQualia, Meiji Seika, Pfizer
Retrospective data, Review, Journal, Head-to-Head: Long-term effectiveness of oral second-generation antipsychotics in patients with schizophrenia and related disorders: a systematic review and meta-analysis of direct head-to-head comparisons. (Pubmed Central) - May 7, 2019
As to psychopathology, clozapine and olanzapine were superior to several other SGAs, while quetiapine and ziprasidone were inferior to several other SGAs...As to prolactin increase, risperidone and amisulpride were significantly worse than several other SGAs...In summary, different long-term SGA efficacy and tolerability patterns emerged. The long-term risk-benefit profiles of specific SGAs need to be tailored to individual patients to optimize maintenance treatment outcomes.
- |||||||||| risperidone / Generic mfg., oxycodone controlled release / Generic mfg., ziprasidone / Generic mfg.
Enrollment open: Reducing the Abuse of Opioids in Drug Users (clinicaltrials.gov) - May 7, 2019
P1, N=25, Recruiting,
Our results indicate that drug-induced FC patterns may be linked to antipsychotic mechanism of action on the molecular level and suggest the technique's value for drug development, especially if our results are extended to a larger number of antipsychotics. Not yet recruiting --> Recruiting
- |||||||||| risperidone / generics
Journal: Psychosis due to idiopathic basal ganglia calcification (Pubmed Central) - Apr 26, 2019
The patient was referred to a psychiatric ward, where the administration of risperidone led to alleviation of his mental state. This case report underlines the importance of an accurate, comprehensive differential diagnosis and the associated significance of neuroimaging.
- |||||||||| risperidone / generics, olanzapine / generics, clozapine / generics
Journal: Sudden death in schizophrenia. (Pubmed Central) - Apr 21, 2019
Future studies should emphasize the genetic aspects as well as clarify the underlying molecular mechanisms of these pathways. Additionally, early detection of those patients at high risk for SUD and discovery of preventive measures should also be emphasized.
- |||||||||| Abilify Maintena (aripiprazole extended release) / Otsuka, Lundbeck
Trial completion date, Trial primary completion date: Study of the Impact of Aripiprazole (Abilify (clinicaltrials.gov) - Apr 19, 2019
P4, N=47, Completed,
However, more high-quality evidence is needed to confirm these results. Trial completion date: Jun 2018 --> Dec 2018 | Trial primary completion date: Dec 2017 --> Nov 2018
- |||||||||| risperidone / generics, olanzapine / generics, quetiapine / generics
Journal: A weight-independent association between atypical antipsychotic medications and obstructive sleep apnea. (Pubmed Central) - Apr 19, 2019
Our data suggest low levels of dorsolateral prefrontal cortex PTGS1 could be associated with the pathophysiology of schizophrenia, and improved therapeutic outcome from treating schizophrenia with antipsychotic drugs augmented with aspirin may be because such treatment lowers cortical PTGS1. While AAP medications are known cause of weight gain as a main risk factor of OSA, our finding demonstrated a weight-independent association between AAP medications and worsening respiration during sleep.
- |||||||||| Journal: A modified QuEChERS approach for the analysis of pharmaceuticals in sediments by LC-Orbitrap HRMS. (Pubmed Central) - Apr 18, 2019
The matrix effect study revealed slight signal suppression that decreased after the cleanup step for 50% of the pharmaceuticals, proving its adequacy to limit matrix interferences, without causing any important loss of relevant analytes. The applicability of the method was successfully tested in sediments from two Greek rivers in northwestern Greece, revealing the presence of paracetamol, risperidone, venlafaxine, citalopram, and carbamazepine and estimating for the first time the potential occurrence of pharmaceuticals in these two aquatic systems.
- |||||||||| Abilify MyCite (aripiprazole tablets embedded with sensor) / Otsuka
Enrollment closed, Trial completion date, Trial primary completion date: A Trial to Explore Acceptance and Performance of Using a Digital Medicine System With Healthcare Professionals and Adults With Schizophrenia, Schizoaffective Disorder, or First Episode Psychosis on an Oral Atypical Antipsychotic (clinicaltrials.gov) - Apr 16, 2019
P4, N=44, Active, not recruiting,
The applicability of the method was successfully tested in sediments from two Greek rivers in northwestern Greece, revealing the presence of paracetamol, risperidone, venlafaxine, citalopram, and carbamazepine and estimating for the first time the potential occurrence of pharmaceuticals in these two aquatic systems. Recruiting --> Active, not recruiting | Trial completion date: Apr 2020 --> May 2019 | Trial primary completion date: Apr 2020 --> May 2019
- |||||||||| Geodon (ziprasidone) / RaQualia, Meiji Seika, Pfizer
Journal: Treatment with antipsychotics in pregnancy: Changes in drug disposition. (Pubmed Central) - Apr 14, 2019
For the remaining antipsychotics (perphenazine, haloperidol, ziprasidone, risperidone and clozapine) our data set was limited, but it indicates that concentrations may decline at least for perphenazine and possibly also for haloperidol. Even though the clinical consequence of the serum concentrations decline remains to be elucidated, our results warrant close clinical monitoring throughout pregnancy, preferentially supported by therapeutic drug monitoring.
- |||||||||| risperidone / generics
Clinical, Review, Journal: Antipsychotics in Hyperthyroid-Related Psychosis: Case Report and Systematic Review. (Pubmed Central) - Apr 11, 2019
Choice of antipsychotic in hyperthyroid-related psychosis should be primarily based on side-effect profile and medical comorbidities. Risperidone is the optimal and seemingly effective choice for treating hyperthyroid-related psychosis in an elderly thyrotoxic patient.
- |||||||||| risperidone / generics
Clinical, Journal: A patient with delusional infestation by proxy: Issues for vulnerable adults. (Pubmed Central) - Apr 11, 2019
...She was diagnosed with delusional infestation (DI) by proxy, and was started on risperidone...Issues of safeguarding vulnerable adults are raised in such cases, suggesting the crucial role of the physician in ensuring patient safety. DI by proxy has been reported in patients with children and animals, but we believe this is the first report of DI by proxy involving a vulnerable adult.
- |||||||||| risperidone / generics, olanzapine / generics, quetiapine / generics
Clinical, Journal: Placebo Effects in the Treatment of Noncognitive Symptoms of Alzheimer's Disease: Analysis of the CATIE-AD Data. (Pubmed Central) - Apr 5, 2019
P=N/A
Symptom trajectories of improvement of behavioral and psychological symptoms of dementia follow the same pattern irrespective of treatment. A 10% improvement at week 2 was the most appropriate predictor of subsequent placebo response at week 8, which may indicate utility for the placebo lead-in phase to minimize future trial failures of treatment for noncognitive symptoms of Alzheimer's disease.
- |||||||||| ciprofloxacin / generics, risperidone / generics
Journal: Human health risk assessment of pharmaceuticals in treated wastewater reused for non-potable applications in Sharjah, United Arab Emirates. (Pubmed Central) - Apr 5, 2019
RQs were highest to lowest in the following order of pharmaceuticals: acetaminophen, metoprolol, ciprofloxacin, erythromycin, ofloxacin, sulfadiazine, sulfamethoxazole, sulfapyridine, risperidone, and sulfamethazine. Such risk assessment findings aid in supporting decisions to optimize wastewater treatment and reuse strategies, as well as safeguard public and environmental health.
- |||||||||| aripiprazole / generics, risperidone / generics
Review, Journal: A systematic review of the use of risperidone, paliperidone and aripiprazole as augmenting agents for obsessive-compulsive disorder. (Pubmed Central) - Apr 5, 2019
Currently, there is evidence to support the use of risperidone, paliperidone and aripiprazole as augmentation agents for OCD in adult samples but more studies with larger samples are needed to assess predictors of response to antipsychotic augmentation and to detect any differential effects between the three agents. At this point in time, the choice of antipsychotic is best determined by the side effect profile of the drug and a patient's medication history.
- |||||||||| risperidone / generics
Journal: Pseudo-Wellens' syndrome in pulmonary embolism. (Pubmed Central) - Apr 5, 2019
There is a reported association between antipsychotic drugs and increased risk of thromboembolism. Risperidone could have potentially contributed to the pulmonary embolism in our patient given the temporal association and absence of risk factors.
- |||||||||| risperidone / generics
Clinical, Journal: Current pharmacotherapy options for conduct disorders in adolescents and children. (Pubmed Central) - Apr 5, 2019
Expert opinion: Atypical antipsychotics (e.g. risperidone) demonstrate evidence for efficacy in CD. Other pharmacotherapies (e.g. mood stabilizers, anticonvulsants, psychostimulants and selective norepinephrine reuptake inhibitors) have a low level of evidence for CD alone, however, can sometimes be effective in managing the symptoms of CD when other psychiatric disorders are also present.
- |||||||||| risperidone / Generic mfg., Egis, clozapine / Generic mfg.
Cardiopulmonary Adverse Effects of Clozapine - 12 Year Retrospective Study of Military Veterans (Regency S-V) - Apr 3, 2019 - Abstract #SIRS2019SIRS_786;
1 Methods 12 year (2002-2017) retrospective chart review of n=530 military veterans - 265 treated with clozapine consecutively matched 1:1 with 265 patients treated with risperidone...Secondly, we hypothesize that a majority of clozapine induced myocarditis cases will occur within the first four weeks of clozapine treatment. We propose that cardiac enzyme monitoring during the first four weeks of clozapine treatment will help reduce the overall incidence and mortality of clozapine induced myocarditis.
- |||||||||| Rational and targeted development of NW-3509, a glutamate modulator for the treatment of patients with poor/ non-response to antipsychotics (Regency P-Q) - Apr 3, 2019 - Abstract #SIRS2019SIRS_767;
These findings support the hypothesis that patients with decreased/non response are unlikely to respond to dopaminergic/ serotoninergic blockade, as noted in failed studies with marketed drugs (risperidone, olanzapine, aripiprazole) or putative antipsychotics (Lu AF35700) that act through non-dopaminergic mechanisms, but may respond to glutamate antagonists...The combination of ineffective doses of NW-3509 and marketed antipsychotics, including clozapine, demonstrated significant effects in animal models of positive and negative symptoms...Neuroimaging techniques assessing cortico-striatal connectivity, the Striatal Connectivity Index, that differentiates patients with schizophrenia who are likely to respond to dopaminergic D2 antagonist treatment versus those patients less likely to respond (Sarpal et Al, JAMA Psych 2015; Sarpal et al, Am J Psych 2015) will be performed at selected centers to characterize these patients. Positive results for evenamide , a selective glutamate modulator without activity at other CNS targets from these trials in poor/non-responders to antipsychotics would validate the hypothesis that glutamatergic, but not dopaminergic , abnormalities underlie non-response in schizophrenia.
- |||||||||| risperidone / Generic mfg., Egis
Immunomodulatory Strategies for Schizophrenia: Preclinical Evidences for Drug Repurposing (Orlando Ballroom L) - Apr 3, 2019 - Abstract #SIRS2019SIRS_728;
Risperidone was used as standard antipsychotic...The IDO inhibitor, MDT and melatonin reversed ketamine-induced behavioral, pro-oxidant and neuroimmune alterations. These experiments open new avenues for the study of drugs targeting tryptophan metabolism in schizophrenia.
- |||||||||| risperidone / Generic mfg., Egis, clozapine / Generic mfg.
Early Intervention is Effective in Halting Developmental Neuropathology and Behavioral Deficits: Lessons From Model Rodents (Regency R) - Apr 3, 2019 - Abstract #SIRS2019SIRS_610;
These results suggest that restoring tonic GABAergic signaling in the vHipp improves schizophrenia-like deficits in a rodent model. . Collectively, the data demonstrate that the neurodevelopmentally compromised brain is remarkably plastic until “symptom” emergence in adolescence/early adulthood, and that intervention during this window is trans-risk factors, trans-symptomatic, and highly effective, achieved with diverse insults, manipulations, and neuropsychopathological outcomes.
- |||||||||| risperidone / Generic mfg., Egis, olanzapine / Generic mfg., quetiapine / Generic mfg.
A Neuroproteomics-Centered Approach to Understand and Reveal Biomarkers to Schizophrenia (Orlando Ballroom L) - Apr 3, 2019 - Abstract #SIRS2019SIRS_498;
Results At first, postmortem brain tissue proteomics from seven different brain regions led us to investigate in vitro the role of the above-mentioned biological processes in cultured oligodendrocytes treated with MK-801 and antipsychotics, to learn more about biochemical processes that may be involved in schizophrenia...Discussion Neuroproteomics may be a powerful asset to reveal novel biological processes in the investigation of complex human disorders as schizophrenia. This has been contributing to knowledge that may lead to more effective medication and potential biomarkers for clinical use.
- |||||||||| risperidone / Generic mfg., Egis
Brazilian Cohort of Antipsychotic-Nave First Episode Psychosis: Research Protocol and Clinical Characteristics (Regency S-V) - Apr 3, 2019 - Abstract #SIRS2019SIRS_482;
All the patients are initially medicated with risperidone and managed by a team of physicians, neuropsychologists and occupational therapists...Discussion As far as we know, this is the biggest Latin American cohort of AN-FEP patients. We aim to make GAPi a reference center in the identification and treatment of the initial stages of psychosis as well as to foment and stimulate the discussion about the adoption of specific strategies for the early treatment in psychiatry in Brazil.
- |||||||||| risperidone / Generic mfg., Egis
Activation of the Immune-Inflammatory Response System and the Compensatory Immune-Regulatory System in Antipsychotic Naive First Episode Psychosis (Regency S-V) - Apr 3, 2019 - Abstract #SIRS2019SIRS_371;
The aim of this study was to examine the IRS and CIRS components, including macrophagic M1, T-helper (Th)-1, Th-2, Th-17 and T-regulatory (Treg) phenotypes, in antipsychotic-naïve first episode psychosis (AN-FEP) before and after risperidone treatment Methods We included 31 AN-FEP and 22 healthy controls...The findings support the hypothesis that, in FEP, the CIRS may contribute to recovery from the acute phase of illness. Enhancing the CIRS may be a new drug target in the treatment of FEP.
- |||||||||| risperidone / Generic mfg., Egis
The Evolution of Long-Acting Antipsychotics use in Qubec Between 2003 and 2017 (Regency S-V) - Apr 3, 2019 - Abstract #SIRS2019SIRS_299;
The use of second-generation LAIs (SGA-LAIs), first introduced in 2003 (Risperidone-Consta), reached 75,1/100,000 in 2017...However, the lack of diagnostic information on the persons who have used these LAIs prevent concluding about their current rates of use in people suffering from SZ and related psychotic disorders as well as on the variations of these rates over the study period. To address these limitations, we are currently planning further analyses based on the public health care system that will combine informations of medication use and diagnostic information on the people with whom these medications are used.
|
